Manish Saxena

Feb 16, 2024 | jamanetwork.com | George Bakris |Manish Saxena |Anil Gupta |Fadi Chalhoub

Key PointsQuestion  Does targeting hepatic angiotensinogen synthesis with the RNA interference therapeutic zilebesiran reduce blood pressure in adults with mild to moderate hypertension? Findings  In a phase 2 trial, subcutaneous zilebesiran doses of 150, 300, or 600 mg every 6 months or 300 mg every 3 months significantly decreased systolic blood pressure at 3 and 6 months vs placebo.

Feb 16, 2024 | jamanetwork.com | Ernesto L. Schiffrin |George Bakris |Manish Saxena |Anil Gupta

Hypertension is the number one cause of disability-adjusted life-years worldwide and the world’s leading risk factor for burden of disease and death.1 It is the most important risk factor for stroke and congestive heart failure, a major cause of kidney failure, and plays an important role in other forms of cardiovascular disease, including atherosclerosis and coronary artery disease.